Trials / Active Not Recruiting
Active Not RecruitingNCT06495918
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration
A Phase 3, Multicenter, Double-Masked, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 825 (estimated)
- Sponsor
- Ocular Therapeutix, Inc. · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects with Neovascular Age- Related Macular Degeneration
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OTX-TKI | Intravitreal Injection of OTX-TKI |
| DRUG | Aflibercept | Intravitreal Injection of 2mg of aflibercept |
| DRUG | Aflibercept | Intravitreal Injection of 8mg of aflibercept |
Timeline
- Start date
- 2024-11-27
- Primary completion
- 2027-01-08
- Completion
- 2027-01-08
- First posted
- 2024-07-11
- Last updated
- 2025-06-17
Locations
97 sites across 4 countries: United States, Argentina, Australia, Puerto Rico
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06495918. Inclusion in this directory is not an endorsement.